You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Hepatocellular carcinoma

Showing 26 - 50 of 9,618
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hepatocellular Carcinoma Trial in Shanghai (Cadonilimab+TACE)

Active, not recruiting
  • Hepatocellular Carcinoma
  • Shanghai, Shanghai, China
    Eastern hepatobilliary surgery hospital
Jun 21, 2023

Key Genes in Hepatocellular Carcinoma

Recruiting
  • Hepatocellular Carcinoma
  • None of intervention
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Feb 26, 2023

Hepatocellular Carcinoma (HCC) Trial (Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE))

Not yet recruiting
  • Hepatocellular Carcinoma (HCC)
  • (no location specified)
Sep 11, 2023

Advanced Hepatocellular Carcinoma Trial (SZ003 CAR-NK)

Not yet recruiting
  • Advanced Hepatocellular Carcinoma
  • SZ003 CAR-NK
  • (no location specified)
Apr 25, 2023

Magnetic Resonance Imaging, Hepatocellular Carcinoma, Screening Trial in Lausanne (MRI)

Recruiting
  • Magnetic Resonance Imaging
  • +3 more
  • MRI
  • Lausanne, Vaud, Switzerland
    Lausanne University Hospital
Apr 12, 2023

Stage IIIA Hepatocellular Carcinoma Trial (Radiotherapy combined with TKI and Anti-PD-1 Antibody)

Not yet recruiting
  • Stage IIIA Hepatocellular Carcinoma
  • Radiotherapy combined with TKI and Anti-PD-1 Antibody
  • (no location specified)
Sep 24, 2023

Advanced Hepatocellular Carcinoma Trial in Guangzhou (adebrelimab, camrelizumab plus apatinib)

Not yet recruiting
  • Advanced Hepatocellular Carcinoma
  • adebrelimab, camrelizumab plus apatinib
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital
Jun 21, 2023

Hepatocellular Carcinoma Trial in Guangzhou (SIRT)

Not yet recruiting
  • Hepatocellular Carcinoma
  • SIRT
  • Guangzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
Aug 9, 2023

Hepatocellular Carcinoma Trial in Wuhan (Sintilimab, Lenvatinib, Transarterial Chemoembolization (TACE))

Not yet recruiting
  • Hepatocellular Carcinoma
  • Wuhan, Hubei, China
    Tongji Hospital, Tongji Medical College, Huazhong University of
Oct 17, 2023

Primary Hepatocellular Carcinoma Trial (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), camrelizumab for

Not yet recruiting
  • Primary Hepatocellular Carcinoma
  • Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
  • camrelizumab for Injection
  • (no location specified)
Nov 13, 2023

Resectable Hepatocellular Carcinoma Trial (Tislelizumab, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Resectable Hepatocellular Carcinoma
  • (no location specified)
Mar 29, 2023

Hepatocellular Carcinoma Trial in Shanghai ([68Ga]Ga-NOTA-RG2 PET Imaging)

Recruiting
  • Hepatocellular Carcinoma
  • [68Ga]Ga-NOTA-RG2 PET Imaging
  • Shanghai, China
    Huashan Hospital
Nov 19, 2023

Hepatocellular Carcinoma Trial in Guangzhou (Bevacizumab combined with Sintilimab, Transcatheter arterial chemoembolization)

Recruiting
  • Hepatocellular Carcinoma
  • Bevacizumab combined with Sintilimab
  • Transcatheter arterial chemoembolization
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Oct 14, 2023

Hepatocellular Carcinoma Trial in Hong Kong (Durvalumab, Tremelimumab, Yttrium-90 radioembolisation)

Recruiting
  • Hepatocellular Carcinoma
  • Hong Kong, Hong Kong
    Department of Clinical Oncology, Queen Mary Hospital
Apr 10, 2023

Hepatocellular Carcinoma Trial in Hangzhou (PVE+cTACE+Camrelizumab+Apatinib, cTACE+Atirizumab+Bevacizumab)

Recruiting
  • Hepatocellular Carcinoma
  • PVE+cTACE+Camrelizumab+Apatinib
  • cTACE+Atirizumab+Bevacizumab
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Feb 26, 2023

Hepatocellular Carcinoma Trial in Shanghai (M-TACE)

Enrolling by invitation
  • Hepatocellular Carcinoma
  • M-TACE
  • Shanghai, Shanghai, China
    Department of Interventional Radiology, Zhongshan Hospital, Fuda
May 24, 2023

Hepatocellular Carcinoma Trial in Seoul (AtezoBev with combined radiotherapy)

Not yet recruiting
  • Hepatocellular Carcinoma
  • AtezoBev with combined radiotherapy
  • Seoul, Korea, Republic of
    Severance hospital
Jun 9, 2023

Potentially Resectable Hepatocellular Carcinoma Trial (FOLFOX-HAIC+Lenvatinib+Envolizumab)

Not yet recruiting
  • Potentially Resectable Hepatocellular Carcinoma
  • (no location specified)
Nov 16, 2023

Hepatocellular Carcinoma Trial in Shanghai (CAR-GPC3 T cells)

Recruiting
  • Hepatocellular Carcinoma
  • CAR-GPC3 T cells
  • Shanghai, China
    Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong Universi
Jun 22, 2023

Hepatocellular Carcinoma Trial in Philadelphia (Hydroxychloroquine, Lipiodol, Placebo)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Philadelphia, Pennsylvania
    Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Apr 21, 2023

Unrescetable Hepatocellular Carcinoma Trial in Tianjin (HAIC+Durvalumab+Tremelimumab+Bevacizumab)

Not yet recruiting
  • Unrescetable Hepatocellular Carcinoma
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital Airport Hospital
May 16, 2023

Carcinoma, Hepatocellular Trial (Therasphere 90Y, Microwave Ablation)

Not yet recruiting
  • Carcinoma, Hepatocellular
  • Therasphere 90Y
  • Microwave Ablation
  • (no location specified)
Jul 12, 2023

Hepatocellular Carcinoma Trial in Taoyuan (ADI-PEG20)

Recruiting
  • Hepatocellular Carcinoma
  • Taoyuan, Taiwan
    Chang Gung Memorial Hospital, Linkou branch
Sep 6, 2023

Hepatocellular Carcinoma Trial (Prednisone)

Not yet recruiting
  • Hepatocellular Carcinoma
  • (no location specified)
Jun 2, 2023

Hepatocellular Carcinoma Non-resectable, Portal Vein Tumor Thrombus, Immune Checkpoint Inhibitors Trial in Nanning (Cadonilimab,

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • +2 more
  • Nanning, Guangxi, China
    First Affiliated Hospital of Guangxi Medical University
Sep 13, 2023